Emerging treatments for primary sclerosing cholangitis

Eduardo A. Rodriguez, Elizabeth J. Carey, Keith Lindor

Research output: Contribution to journalReview article

3 Citations (Scopus)

Abstract

Introduction: Primary sclerosing cholangitis (PSC) is a chronic, cholestatic, idiopathic liver disease that can progress to end-stage liver disease, cirrhosis and cholangiocarcinoma. PSC is an uncommon and highly heterogeneous disease, associated with inflammatory bowel disease and a complex pathophysiology. To date, no medical therapies have proved effective. The only available treatment for end-stage PSC is liver transplant, but recurrence is a significant complication. Areas covered: This review will explore previously tested treatments, discuss current treatment strategies and present viewpoints about future emerging therapies in PSC. We searched PubMed using the noted keywords. We included data from full-text articles published in English. Further relevant articles were identified from the reference lists of review articles. Expert commentary: The development of new therapies in PSC has been challenging. However, with greater awareness of the disease nowadays, new insights into the disease may help in the design of future therapeutic agents in PSC and ultimately in effective therapies.

Original languageEnglish (US)
Pages (from-to)451-459
Number of pages9
JournalExpert Review of Gastroenterology and Hepatology
Volume11
Issue number5
DOIs
StatePublished - May 4 2017

Fingerprint

Sclerosing Cholangitis
Therapeutics
End Stage Liver Disease
Cholangiocarcinoma
Inflammatory Bowel Diseases
PubMed
Liver Cirrhosis
Liver Diseases
Transplants
Recurrence
Liver

Keywords

  • antibiotics
  • antifibrotic agents
  • fecal microbiota transplantation
  • obeticholic acid
  • Primary sclerosing cholangitis
  • ursodeoxycholic acid

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology

Cite this

Emerging treatments for primary sclerosing cholangitis. / Rodriguez, Eduardo A.; Carey, Elizabeth J.; Lindor, Keith.

In: Expert Review of Gastroenterology and Hepatology, Vol. 11, No. 5, 04.05.2017, p. 451-459.

Research output: Contribution to journalReview article

Rodriguez, Eduardo A. ; Carey, Elizabeth J. ; Lindor, Keith. / Emerging treatments for primary sclerosing cholangitis. In: Expert Review of Gastroenterology and Hepatology. 2017 ; Vol. 11, No. 5. pp. 451-459.
@article{2105a5574abb46a7b34a3a66a1b50a55,
title = "Emerging treatments for primary sclerosing cholangitis",
abstract = "Introduction: Primary sclerosing cholangitis (PSC) is a chronic, cholestatic, idiopathic liver disease that can progress to end-stage liver disease, cirrhosis and cholangiocarcinoma. PSC is an uncommon and highly heterogeneous disease, associated with inflammatory bowel disease and a complex pathophysiology. To date, no medical therapies have proved effective. The only available treatment for end-stage PSC is liver transplant, but recurrence is a significant complication. Areas covered: This review will explore previously tested treatments, discuss current treatment strategies and present viewpoints about future emerging therapies in PSC. We searched PubMed using the noted keywords. We included data from full-text articles published in English. Further relevant articles were identified from the reference lists of review articles. Expert commentary: The development of new therapies in PSC has been challenging. However, with greater awareness of the disease nowadays, new insights into the disease may help in the design of future therapeutic agents in PSC and ultimately in effective therapies.",
keywords = "antibiotics, antifibrotic agents, fecal microbiota transplantation, obeticholic acid, Primary sclerosing cholangitis, ursodeoxycholic acid",
author = "Rodriguez, {Eduardo A.} and Carey, {Elizabeth J.} and Keith Lindor",
year = "2017",
month = "5",
day = "4",
doi = "10.1080/17474124.2017.1293524",
language = "English (US)",
volume = "11",
pages = "451--459",
journal = "Expert Review of Gastroenterology and Hepatology",
issn = "1747-4124",
publisher = "Expert Reviews Ltd.",
number = "5",

}

TY - JOUR

T1 - Emerging treatments for primary sclerosing cholangitis

AU - Rodriguez, Eduardo A.

AU - Carey, Elizabeth J.

AU - Lindor, Keith

PY - 2017/5/4

Y1 - 2017/5/4

N2 - Introduction: Primary sclerosing cholangitis (PSC) is a chronic, cholestatic, idiopathic liver disease that can progress to end-stage liver disease, cirrhosis and cholangiocarcinoma. PSC is an uncommon and highly heterogeneous disease, associated with inflammatory bowel disease and a complex pathophysiology. To date, no medical therapies have proved effective. The only available treatment for end-stage PSC is liver transplant, but recurrence is a significant complication. Areas covered: This review will explore previously tested treatments, discuss current treatment strategies and present viewpoints about future emerging therapies in PSC. We searched PubMed using the noted keywords. We included data from full-text articles published in English. Further relevant articles were identified from the reference lists of review articles. Expert commentary: The development of new therapies in PSC has been challenging. However, with greater awareness of the disease nowadays, new insights into the disease may help in the design of future therapeutic agents in PSC and ultimately in effective therapies.

AB - Introduction: Primary sclerosing cholangitis (PSC) is a chronic, cholestatic, idiopathic liver disease that can progress to end-stage liver disease, cirrhosis and cholangiocarcinoma. PSC is an uncommon and highly heterogeneous disease, associated with inflammatory bowel disease and a complex pathophysiology. To date, no medical therapies have proved effective. The only available treatment for end-stage PSC is liver transplant, but recurrence is a significant complication. Areas covered: This review will explore previously tested treatments, discuss current treatment strategies and present viewpoints about future emerging therapies in PSC. We searched PubMed using the noted keywords. We included data from full-text articles published in English. Further relevant articles were identified from the reference lists of review articles. Expert commentary: The development of new therapies in PSC has been challenging. However, with greater awareness of the disease nowadays, new insights into the disease may help in the design of future therapeutic agents in PSC and ultimately in effective therapies.

KW - antibiotics

KW - antifibrotic agents

KW - fecal microbiota transplantation

KW - obeticholic acid

KW - Primary sclerosing cholangitis

KW - ursodeoxycholic acid

UR - http://www.scopus.com/inward/record.url?scp=85017548145&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85017548145&partnerID=8YFLogxK

U2 - 10.1080/17474124.2017.1293524

DO - 10.1080/17474124.2017.1293524

M3 - Review article

VL - 11

SP - 451

EP - 459

JO - Expert Review of Gastroenterology and Hepatology

JF - Expert Review of Gastroenterology and Hepatology

SN - 1747-4124

IS - 5

ER -